Advancing Bispecific & Multi-Specific T-Cell Engagers to Maximize Tumor-Specific Engagement for More Potent Therapeutics

11:29 am - Thursday 25th June 2026

Speakers:

Michael Song
Director, CMC Upstream Process Development
Janux Therapeutics